PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Clinical trials for PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE explained in plain language.
Never miss a new study
Get alerted when new PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE trials appear
Sign up with your email to follow new studies for PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug KarXT tested for Alzheimer's psychosis in Year-Long safety study
Disease control Recruiting nowThis study looks at the long-term safety of a drug called KarXT for people with Alzheimer's disease who also have psychosis (hallucinations or delusions). About 800 people who completed earlier studies will take KarXT for up to 52 weeks. Researchers will track side effects to see…
Matched conditions: PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Hope for Alzheimer's psychosis: new drug aims to stop relapses
Disease control Recruiting nowThis study tests an experimental drug called KarXT to see if it can prevent the return of psychosis (hallucinations, delusions) in people with Alzheimer's disease. About 410 participants aged 55-90 will receive either KarXT or a placebo for 38 weeks. The goal is to see if KarXT h…
Matched conditions: PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New hope for Alzheimer's psychosis: 52-Week safety trial launches
Symptom relief Recruiting nowThis study looks at the long-term safety of an experimental drug, ML007C-MA, for people with Alzheimer's disease who experience hallucinations and delusions. It is an open-label extension, meaning all participants will receive the drug for up to 52 weeks. The goal is to see if th…
Matched conditions: PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Phase: PHASE2 • Sponsor: MapLight Therapeutics • Aim: Symptom relief
Last updated May 17, 2026 09:27 UTC
-
Hope for Alzheimer's patients: new drug targets psychosis
Symptom relief Recruiting nowThis study tests a drug called KarXT to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease. About 500 participants aged 55 to 90 with mild to severe Alzheimer's and moderate to severe psychosis will receive either KarXT or a placebo. The g…
Matched conditions: PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Symptom relief
Last updated May 17, 2026 09:08 UTC
-
New hope for Alzheimer's psychosis: drug trial targets hallucinations and delusions
Symptom relief Recruiting nowThis study tests an experimental drug, ITI-1284, to see if it can safely reduce psychosis symptoms (like delusions and hallucinations) in people with Alzheimer's disease. About 370 participants will receive either the drug or a placebo, and researchers will measure changes in sym…
Matched conditions: PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Phase: PHASE2 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Symptom relief
Last updated May 11, 2026 20:52 UTC
-
New hope for Alzheimer's psychosis: drug targets troubling hallucinations
Symptom relief Recruiting nowThis study tests an experimental drug, ML-007C-MA, to see if it can reduce hallucinations and delusions in people with Alzheimer's disease. About 300 participants aged 55 to 90 will receive either the drug or a placebo. The goal is to improve quality of life by easing these distr…
Matched conditions: PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE
Phase: PHASE2 • Sponsor: MapLight Therapeutics • Aim: Symptom relief
Last updated May 11, 2026 20:39 UTC